Cargando…

Survival After Combining Stereotactic Body Radiation Therapy and Tyrosine Kinase Inhibitors in Patients With Metastatic Renal Cell Carcinoma

BACKGROUND: Stereotactic body radiation therapy (SBRT) and tyrosine kinase inhibitors (TKIs) are effective treatments for metastatic renal cell carcinoma, but data on combining these two modalities are scarce. We aimed to investigate the survival outcomes of SBRT plus TKIs. METHODS: Data of patients...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Yang, Zhang, Zhiling, Han, Hui, Guo, Shengjie, Liu, Zhuowei, Liu, Mengzhong, Zhou, Fangjian, Dong, Pei, He, Liru
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7937906/ https://www.ncbi.nlm.nih.gov/pubmed/33692951 http://dx.doi.org/10.3389/fonc.2021.607595

Ejemplares similares

Survival Outcomes After Adding Stereotactic Body Radiotherapy to Metastatic Renal Cell Carcinoma Patients Treated With Tyrosine Kinase Inhibitors
por: He, Liru, et al.
Publicado: (2020)

Stereotactic body radiotherapy in combination with non-frontline PD-1 inhibitors and targeted agents in metastatic renal cell carcinoma
por: Liu, Yang, et al.
Publicado: (2021)

Survival Outcomes and Prognostic Analysis Following Greater Cytoreductive Radiotherapy in Patients With Metastatic Prostate Cancer
por: Zhang, Zitong, et al.
Publicado: (2020)

Metastasis-directed stereotactic body radiotherapy for oligometastatic renal cell carcinoma: extent of tumor burden eradicated by radiotherapy
por: Liu, Yang, et al.
Publicado: (2021)

Impact of Time to Castration Resistance on Cytoreductive Radiotherapy in Metastatic Castration-Resistant Prostate Cancer
por: Mai, Lixin, et al.
Publicado: (2020)

Whole Brain Radiation Therapy Plus Stereotactic Radiosurgery in the Treatment of Brain Metastases Leading to Improved Survival in Patients With Favorable Prognostic Factors
por: Khan, Muhammad, et al.
Publicado: (2019)

Stereotactic Radiation for Treating Primary and Metastatic Neoplasms of the Spinal Cord
por: Liu, Elisa K., et al.
Publicado: (2020)

Stereotactic body radiotherapy-induced abscopal effect twice after pembrolizumab failure in hereditary leiomyomatosis and renal cell carcinoma: a case report with genetic and immunologic analysis
por: Zhang, Xinyue, et al.
Publicado: (2021)

Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy Cost-Effectiveness Results
por: Bijlani, Akash, et al.
Publicado: (2013)

Stereotactic Body Radiotherapy for the Treatment of Renal Tumors()
por: Hanzly, Michael, et al.
Publicado: (2014)

The Association of Radiation Dose With Overall Survival for Patients Treated With Prostate Stereotactic Body Radiation Therapy
por: Waters, Michael R, et al.
Publicado: (2023)

Stereotactic body radiation therapy in the treatment of oligometastatic prostate cancer
por: Ahmed, Kamran A., et al.
Publicado: (2013)

Dysuria Following Stereotactic Body Radiation Therapy for Prostate Cancer
por: Janowski, Einsley-Marie, et al.
Publicado: (2015)

Significant Correlation Between Overall Survival and Mean Lung Dose in Lung Stereotactic Body Radiation Therapy (SBRT)
por: Dupic, Guillaume, et al.
Publicado: (2020)

Prognostic value of normal sodium levels in patients with metastatic renal cell carcinoma receiving tyrosine kinase inhibitors
por: Roviello, Giandomenico, et al.
Publicado: (2022)

Metastatic renal cell carcinoma of the native kidney in a renal transplant recipient: Revisiting the era of tyrosine kinase inhibitors – Case report
por: Suso-Palau, Daniel, et al.
Publicado: (2022)

Usefulness of Stereotactic Body Radiation Therapy for Treatment of Adrenal Gland Metastases
por: Scouarnec, Cyrielle, et al.
Publicado: (2019)

Bothersome Hematospermia Following Stereotactic Body Radiation Therapy for Prostate Cancer
por: Shah, Sarthak, et al.
Publicado: (2021)

Survival Outcomes of Patients Treated with Hypofractionated Stereotactic Body Radiation Therapy for Parotid Gland Tumors: a Retrospective Analysis
por: Karam, Sana D., et al.
Publicado: (2012)

Survival and Control Prognosticators of Recurrent Gynecological Malignancies of the Pelvis and Para-aortic Region Treated with Stereotactic Body Radiation Therapy
por: Hasan, Shaakir, et al.
Publicado: (2016)

Association of baseline self-reported fatigue with overall survival after stereotactic body radiation therapy for localized prostate cancer
por: Simhal, Rishabh K., et al.
Publicado: (2022)

Frameless stereotactic body radiation therapy for multiple lung metastases
por: Li, Qilin, et al.
Publicado: (2014)

Stereotactic Body Radiation Therapy for Locally Progressive and Recurrent Pancreatic Cancer after Prior Radiation
por: Sutera, Philip, et al.
Publicado: (2018)

Durable Complete Remission With Combination of Stereotactic Body Radiation Therapy (SBRT) and Talimogene Laherparepvec (TVEC) Followed by Ipilimumab in Refractory Metastatic Melanoma
por: Wolfe, Zachary, et al.
Publicado: (2022)

Impact of Tyrosine Kinase Inhibitors (TKIs) Combined With Radiation Therapy for the Management of Brain Metastases From Renal Cell Carcinoma
por: Khan, Muhammad, et al.
Publicado: (2020)

Editorial: Stereotactic body radiotherapy for lung cancer
por: Liu, An, et al.
Publicado: (2023)

Feasibility and dosimetric evaluation of single- and multi-isocentre stereotactic body radiation therapy for multiple liver metastases
por: Tang, Chunbo, et al.
Publicado: (2023)

Impact of Sarcopenia on Survival in Patients With Early-Stage Lung Cancer Treated With Stereotactic Body Radiation Therapy
por: Taylor, James M, et al.
Publicado: (2020)

Special issue “The advance of solid tumor research in China”: 68Ga‐PSMA‐11 PET/CT for evaluating primary and metastatic lesions in different histological subtypes of renal cell carcinoma
por: Li, Yilin, et al.
Publicado: (2022)

Radiation-induced organizing pneumonia after stereotactic body radiotherapy for lung tumor
por: Ochiai, Satoru, et al.
Publicado: (2015)

Editorial: The Evolving Landscape of Stereotactic Body Radiation Therapy for the Management of Prostate Cancer
por: Blacksburg, Seth R., et al.
Publicado: (2020)

Phase II Clinical Trial of Robotic Stereotactic Body Radiosurgery for Metastatic Gynecologic Malignancies
por: Kunos, Charles A., et al.
Publicado: (2012)

Abscopal effect in metastatic breast cancer treated with stereotactic body radiotherapy in the absence of immunotherapy
por: Kim, Jae Sik, et al.
Publicado: (2023)

Rationale for Involved Field Stereotactic Body Radiation Therapy-Enhanced Intermittent Androgen Deprivation Therapy in Hormone-Sensitive Nodal Oligo-Recurrent Prostate Cancer Following Prostate Stereotactic Body Radiation Therapy
por: Carrasquilla, Michael, et al.
Publicado: (2021)

Stereotactic body radiotherapy for Stage I lung cancer with chronic obstructive pulmonary disease: special reference to survival and radiation-induced pneumonitis
por: Inoue, Toshihiko, et al.
Publicado: (2015)

Salvage lenvatinib/everolimus combination therapy after immune checkpoint inhibitor and VEGFR tyrosine kinase inhibitor for metastatic renal cell carcinoma
por: Kwok, Christopher, et al.
Publicado: (2023)

Prognosis and Risk Factors of Recurrence in HBV-Related Small Hepatocellular Carcinoma After Stereotactic Body Radiation Therapy
por: Han, Yifan, et al.
Publicado: (2022)

Tyrosine Kinase Inhibitor Cabozantinib Inhibits Murine Renal Cancer by Activating Innate and Adaptive Immunity
por: Liu, Hongyan, et al.
Publicado: (2021)

The Comparison of Stereotactic Body Radiation Therapy and Intensity-Modulated Radiation Therapy for Prostate Cancer by NCCN Risk Groups
por: Ricco, Anthony, et al.
Publicado: (2016)

Stereotactic Body Radiation Therapy for Patients with Heavily Pretreated Liver Metastases and Liver Tumors
por: Lanciano, Rachelle, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_77m8vkeb8n5io1qfdbcg7drf8b